These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
276 related items for PubMed ID: 15112269
21. [Expression of vascular endothelial growth factor and its receptors KDR and Flt1 in acute myeloid leukemia]. Wang Y, Xiao ZJ, Liu P, Yang C, Yang RC, Cai YL, Han ZC. Zhonghua Xue Ye Xue Za Zhi; 2003 May; 24(5):249-52. PubMed ID: 12859876 [Abstract] [Full Text] [Related]
23. Characteristics of acute myeloid leukemia with myelodysplasia-related changes: A retrospective analysis in a cohort of Chinese patients. Xu XQ, Wang JM, Gao L, Qiu HY, Chen L, Jia L, Hu XX, Yang JM, Ni X, Chen J, Lü SQ, Zhang WP, Song XM. Am J Hematol; 2014 Sep; 89(9):874-81. PubMed ID: 24861848 [Abstract] [Full Text] [Related]
24. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia. Hofmann WK, Heil G, Zander C, Wiebe S, Ottmann OG, Bergmann L, Hoeffken K, Fischer JT, Knuth A, Kolbe K, Schmoll HJ, Langer W, Westerhausen M, Koelbel CB, Hoelzer D, Ganser A. Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346 [Abstract] [Full Text] [Related]
28. Combination therapy with DNA methyltransferase inhibitors in hematologic malignancies. Gore SD. Nat Clin Pract Oncol; 2005 Dec; 2 Suppl 1():S30-5. PubMed ID: 16341238 [Abstract] [Full Text] [Related]
29. Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth. Ebos JM, Lee CR, Bogdanovic E, Alami J, Van Slyke P, Francia G, Xu P, Mutsaers AJ, Dumont DJ, Kerbel RS. Cancer Res; 2008 Jan 15; 68(2):521-9. PubMed ID: 18199548 [Abstract] [Full Text] [Related]
30. [Intensive chemotherapy in myelodysplastic syndromes]. Dombret H. Pathol Biol (Paris); 1997 Oct 15; 45(8):627-35. PubMed ID: 9569928 [Abstract] [Full Text] [Related]
31. Over-expression of tumor necrosis factor-alpha in bone marrow biopsies from patients with myelodysplastic syndromes: relationship to anemia and prognosis. Stifter G, Heiss S, Gastl G, Tzankov A, Stauder R. Eur J Haematol; 2005 Dec 15; 75(6):485-91. PubMed ID: 16313260 [Abstract] [Full Text] [Related]
32. Dynamics of telomere erosion and its association with genome instability in myelodysplastic syndromes (MDS) and acute myelogenous leukemia arising from MDS: a marker of disease prognosis? Sieglová Z, Zilovcová S, Cermák J, Ríhová H, Brezinová D, Dvoráková R, Marková M, Maaloufová J, Sajdová J, Brezinová J, Zemanová Z, Michalová K. Leuk Res; 2004 Oct 15; 28(10):1013-21. PubMed ID: 15289012 [Abstract] [Full Text] [Related]
33. [Prognostic factor analysis of 77 old patients with acute myelogenous leukemia]. Shao B, Gao YR, Wang C, Yan SK, Cai Q, Jiang JL, Yang J, Bai HT, Zhao M, Zhao CX. Ai Zheng; 2006 Aug 15; 25(8):1007-12. PubMed ID: 16965684 [Abstract] [Full Text] [Related]
34. Circulating serum levels of angiogenic factors and vascular endothelial growth factor receptors 1 and 2 in melanoma patients. Tas F, Duranyildiz D, Oguz H, Camlica H, Yasasever V, Topuz E. Melanoma Res; 2006 Oct 15; 16(5):405-11. PubMed ID: 17013089 [Abstract] [Full Text] [Related]
35. Wilms' tumor-1 transcript in peripheral blood helps diagnose acute myeloid leukemia and myelodysplastic syndrome in patients with pancytopenia. Yamauchi T, Matsuda Y, Takai M, Tasaki T, Hosono N, Negoro E, Ikegaya S, Takagi K, Kishi S, Yoshida A, Urasaki Y, Ueda T. Anticancer Res; 2012 Oct 15; 32(10):4479-83. PubMed ID: 23060576 [Abstract] [Full Text] [Related]
36. Leukemic cluster growth in culture is an independent risk factor for acute myeloid leukemia and short survival in patients with myelodysplastic syndrome. Bernimoulin M, Stern M, Tichelli A, Jotterand M, Gratwohl A, Nissen C. Acta Haematol; 2008 Oct 15; 119(4):226-35. PubMed ID: 18566541 [Abstract] [Full Text] [Related]
37. Prognostic factors for patients with acute myeloid leukaemia or high-risk myelodysplastic syndromes undergoing myeloablative or non-myeloablative allogeneic blood stem cell transplantation. Graef T, Vaupel M, Fenk R, Ruf L, Zohren F, Germing U, Haas R, Kobbe G. Hematol Oncol; 2007 Dec 15; 25(4):170-7. PubMed ID: 17579887 [Abstract] [Full Text] [Related]
38. Reasons for treating secondary AML as de novo AML. Ostgård LS, Kjeldsen E, Holm MS, Brown Pde N, Pedersen BB, Bendix K, Johansen P, Kristensen JS, Nørgaard JM. Eur J Haematol; 2010 Sep 15; 85(3):217-26. PubMed ID: 20456491 [Abstract] [Full Text] [Related]
39. Results of a multicenter phase II trial for older patients with c-Kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C and Imatinib. Heidel F, Cortes J, Rücker FG, Aulitzky W, Letvak L, Kindler T, Huber C, Döhner H, Kantarjian H, Fischer T. Cancer; 2007 Mar 01; 109(5):907-14. PubMed ID: 17285599 [Abstract] [Full Text] [Related]
40. Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage I non-small-cell lung cancer. Seto T, Higashiyama M, Funai H, Imamura F, Uematsu K, Seki N, Eguchi K, Yamanaka T, Ichinose Y. Lung Cancer; 2006 Jul 01; 53(1):91-6. PubMed ID: 16697074 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]